Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
Elaine Y. Chung, … , Mitchell J. Weiss, Andrei Thomas-Tikhonenko
Elaine Y. Chung, … , Mitchell J. Weiss, Andrei Thomas-Tikhonenko
Published May 1, 2012
Citation Information: J Clin Invest. 2012;122(6):2257-2266. https://doi.org/10.1172/JCI45851.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 29

CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis

  • Text
  • PDF
Abstract

PAX5, a B cell–specific transcription factor, is overexpressed through chromosomal translocations in a subset of B cell lymphomas. Previously, we had shown that activation of immunoreceptor tyrosine-based activation motif (ITAM) proteins and B cell receptor (BCR) signaling by PAX5 contributes to B-lymphomagenesis. However, the effect of PAX5 on other oncogenic transcription factor-controlled pathways is unknown. Using a MYC-induced murine lymphoma model as well as MYC-transformed human B cell lines, we found that PAX5 controls c-MYC protein stability and steady-state levels. This promoter-independent, posttranslational mechanism of c-MYC regulation was independent of ITAM/BCR activity. Instead it was controlled by another PAX5 target, CD19, through the PI3K-AKT-GSK3β axis. Consequently, MYC levels in B cells from CD19-deficient mice were sharply reduced. Conversely, reexpression of CD19 in murine lymphomas with spontaneous silencing of PAX5 boosted MYC levels, expression of its key target genes, cell proliferation in vitro, and overall tumor growth in vivo. In human B-lymphomas, CD19 mRNA levels were found to correlate with those of MYC-activated genes. They also negatively correlated with the overall survival of patients with lymphoma in the same way that MYC levels do. Thus, CD19 is a major BCR-independent regulator of MYC-driven neoplastic growth in B cell neoplasms.

Authors

Elaine Y. Chung, James N. Psathas, Duonan Yu, Yimei Li, Mitchell J. Weiss, Andrei Thomas-Tikhonenko

×

Figure 1

PAX5 regulates c-MYC protein levels.

Options: View larger image (or click on image) Download as PowerPoint
PAX5 regulates c-MYC protein levels.
All panels represent immunoblotting...
All panels represent immunoblotting analyses of proteins indicated. Actin was used as a loading control. (A) P493-6 cells either untreated (0 hours) or treated with Dox for indicated intervals prior to harvesting. (B) MYC5 cells infected with either the empty MIGR1 vector (GFP) or PAX5-MIGR1 (PAX5). Protein lysates were prepared 24 and 48 hours after infection. (C) Protein lysates were obtained from MYC tumors samples described previously (27). Prior to implantation, MYC5 cells were infected with either the empty MIGR1 vector or PAX5ERMIGR1 (PAX5ER). (D) P493-6 cells electroporated using various anti-PAX5 (PAX5) or control (Ctrl) siRNAs. (E) P493-6 cells were electroporated (e/p) with 1 μM of either control or anti-PAX5 siRNA, and lysates were harvested 24 and 48 hours after electroporation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Posted by 2 X users
Referenced in 16 patents
On 1 Facebook pages
Referenced in 2 Wikipedia pages
92 readers on Mendeley
See more details